Eye injuries in the elderly from consumer products in the United States: 2001–2007

2012 ◽  
Vol 251 (3) ◽  
pp. 645-651 ◽  
Author(s):  
Allison J. Chen ◽  
Julia G. Kim ◽  
James G. Linakis ◽  
Michael J. Mello ◽  
Paul B. Greenberg
Author(s):  
Jennifer Moren Cross ◽  
Russell Griffin ◽  
Cynthia Owsley ◽  
Gerald McGwin

2001 ◽  
Vol 24 (1) ◽  
pp. 66-69 ◽  
Author(s):  
PETER N. SMITH ◽  
HUMBERTO VIDAILLET ◽  
PARAM P. SHARMA ◽  
JOHN J. HAYES ◽  
JOHN R. SCHMELZER

2000 ◽  
Vol 3 (5) ◽  
pp. 352-353
Author(s):  
K Langa ◽  
J Hayman ◽  
M Kabeto ◽  
M Chernew ◽  
S Katz ◽  
...  

Author(s):  
Frederick J. Diedrich ◽  
Christine T. Wood ◽  
Thomas J. Ayres

Consumer products currently sold in the United States often come with extensive safety information, but the presentation of large amounts of such material was not always the case. We reviewed federally mandated hazard labeling as it evolved during the 20th century by documenting changes in labeling requirements for home-use products prescribed by federal statutes. Our review indicated that during the course of the 20th century, there was a dramatic change in the presence, prevalence and specificity of hazard warning requirements. In the early years, Congress concentrated on truth in labeling of contents and quality. This labeling identified hazardous agents in some products. However, as the century progressed, Congress gradually added requirements that could include descriptions of the mechanisms, consequences, and means for avoidance of such hazards. Moreover, the 1960's and especially the 1970's brought a dramatic expansion in the number and types of products required to bear hazard labels.


1990 ◽  
Vol 28 (8) ◽  
pp. 31-32

Pneumococcal pneumonia probably affects about one in every thousand adults each year. Like other serious pneumococcal infection, it is more common and severe in the elderly, in those without a functional spleen (including patients with sickle-cell disease,1) and in patients with a variety of chronic diseases. In the United States a 23-valent pneumococcal vaccine was introduced in 1983, replacing a 14-valent vaccine; it is now recommended there for large groups of people.2 This newer 23-valent vaccine (Pneumovax-II - MSD) was licensed in Britain last May. Its use should be considered for those at special risk of pneumococcal disease.3–5


Sign in / Sign up

Export Citation Format

Share Document